PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced
According to data from Benzinga Pro, during Q2, Strata Skin Sciences's (NASDAQ:SSKN) reported sales totaled $7.38 million. Despite a 61.41% increase in earnings, the company posted a loss of $923.00 thousand.
Gainers
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.